InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the ” Global Colony Stimulating Factors Market By Type (Macrophage–Colony-Stimulating Factor (M-CSF), Multiple-Colony-Stimulating Factor or Interleukin 3 (IL-3), Granulocyte-Macrophage–Colony-Stimulating Factor (GM-CSF) and Granulocyte–Colony-Stimulating Factor (G-CSF), drug (Pegfilgrastim, Tbo-filgrastim, Sargramostim and Filgrastim), Application (Aplastic Anemia, Bone Marrow Transplantation, Neutropenia, Neutropenia Associated with Chemotherapy, Neutropenia Associated with Radiation and Peripheral Progenitor Cell Transplantations), Dosage (Injection, Tablets, Capsules and Others), Route of Administration (Intravenous, Subcutaneous, Oral and Others), End-users ( Hospitals, Specialty Clinics, Homecare and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others)- Trends, Industry Competition Analysis, Revenue and Forecast To 2031.”
The global Colony Stimulating Factors market is estimated to exhibit a CAGR of 7.90% during the forecast period.
Request For Free Sample Report:
https://www.insightaceanalytic.com/request-sample/1382
Colony Stimulating Factors (CSFs) are hormone-like substances that play a crucial role in promoting the growth and development of immune cells capable of combating infections. These factors are produced by various cell types within the body, circulating and binding to specific receptors on target cells. The ability of CSFs to stimulate the production of white blood cells makes them valuable therapeutics, particularly for patients whose immune systems have been weakened by chemotherapy or specific immunodeficiency disorders.
The expansion of the global CSF market is primarily driven by increased government investment in healthcare, a rising incidence of cancer, and growing awareness of the availability of various treatment options for cancer. Additionally, the growing demand for prophylactic CSF is an important factor contributing to market growth.
List of Prominent Players in the Colony Stimulating Factors Market:
- Intas Pharmaceuticals Ltd.
- Sanofi
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- GlaxoSmithKline plc
- Biocon
- Reddy’s Laboratories Ltd.
- Amgen Inc.
- Merck KGaA
- Takeda Pharmaceutical Company Limited
- Thermo Fisher Scientific Inc.
- Stada Arzneimittel AG
- Emcure Pharmaceuticals Limited.
- Celltrion, Inc
- Biocad
- Coherus BioSciences
- Johnson & Johnson Private Limited
- Eli Lilly and Company.
- Abbott
Market Dynamics:
Drivers-
The colony-stimulating factor (CSF) market is projected to experience significant growth due to the increasing global incidence of cancer. Cancer remains the second leading cause of death worldwide, responsible for approximately one in every six deaths. According to the International Agency for Research on Cancer (IARC), by 2040, population aging and growth will lead to an estimated 16.3 million cancer-related deaths and 27.5 million new cancer cases globally. Over 70% of cancer-related deaths occur in low- and middle-income countries.
Enquiry Before Buying:
https://www.insightaceanalytic.com/enquiry-before-buying/1382
Challenges:
Despite the growth potential, the CSF market faces several challenges, particularly the high cost associated with these treatments. The adoption of CSFs is also hindered by the shortage of skilled healthcare professionals and inadequate healthcare infrastructure in emerging markets.
Regional Trends:
The North American CSF market is anticipated to capture a significant revenue share and experience a high compound annual growth rate (CAGR) due to the increasing prevalence of cancer in the region. The market’s growth will be further supported by the presence of major industry players and a robust healthcare infrastructure. Additionally, improvements in clinical practices, enhanced access to cancer therapies, and advances in cancer research within the United States will contribute to this expansion. The National Cancer Institute (NCI) reports approximately 1,735,350 new cancer cases in the U.S., fueling the demand for colony-stimulating factors.
Recent Developments:
In June 2019, A US-based pharmaceutical company named Pfizer Inc. purchased Array BioPharma Inc. for $48 per share in cash or roughly $11.4 billion for the entire organization. The innovative biopharmaceutical business of Pfizer is strengthened by this acquisition, which is predicted to hasten its growth trajectory over the long run.
Get Specific Chapter/Information From The Report:
https://www.insightaceanalytic.com/customisation/1382
Segmentation of Colony Stimulating Factors Market-
By Type-
- Macrophage–Colony-Stimulating Factor (M-CSF)
- Multiple-Colony-Stimulating Factor or Interleukin 3 (IL-3)
- Granulocyte-Macrophage–Colony-Stimulating Factor (GM-CSF)
- Granulocyte–Colony-Stimulating Factor (G-CSF)
By Drug-
- Pegfilgrastim
- Tbo-filgrastim
- Sargramostim
- Filgrastim
By Application-
- Aplastic Anemia
- Bone Marrow Transplantation
- Neutropenia
- Neutropenia Associated with Chemotherapy
- Neutropenia Associated with Radiation
- Peripheral Progenitor Cell Transplantations
By Dosage-
- Injection
- Tablets
- Capsule
- Others
By Route of Administration-
- Intravenous
- Subcutaneous
- Oral
- Others
By End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Get More Information :
https://www.insightaceanalytic.com/report/global-colony-stimulating-factors-market/1382
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.
Contact Us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace
